Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma (Q30641952)

15 September 2017

0 references

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma (English)

1 reference

Acute decompensated heart failure

15 September 2017

0 references

1 reference

1 reference

autoimmune myocarditis

1 reference

based on heuristic

inferred from title

1 reference

Heinz Läubli

1

1 reference

15 September 2017

Cathrin Balmelli

2

1 reference

15 September 2017

Matthias Bossard

3

1 reference

15 September 2017

Otmar Pfister

4

1 reference

15 September 2017

Kathrin Glatz

5

1 reference

15 September 2017

Alfred Zippelius

6

1 reference

15 September 2017

21 April 2015

1 reference

Journal for Immunotherapy of Cancer

15 September 2017

1 reference

15 September 2017

3

1 reference

15 September 2017

11

1 reference

Creative Commons Attribution 4.0 International

15 September 2017

start time

21 April 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s40425-015-0057-1

0 references

cites work

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Nivolumab in previously untreated melanoma without BRAF mutation

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Immune modulation in cancer with antibodies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Nivolumab plus ipilimumab in advanced melanoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

20 June 2018

Update on myocarditis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

20 June 2018

Acute viral myocarditis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Progress in human tumour immunology and immunotherapy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4404586

20 June 2018

1 reference

https://api.crossref.org/works/10.1186%2FS40425-015-0057-1

PD-1 deficiency results in the development of fatal myocarditis in MRL mice

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FS40425-015-0057-1

Antitumour immunity gets a boost

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FS40425-015-0057-1

10.1186/S40425-015-0057-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

15 September 2017

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/s40425-015-0057-1

1 reference

15 September 2017

1 reference